Marshall Wace LLP Sells 18,763 Shares of AxoGen, Inc. (NASDAQ:AXGN)

Marshall Wace LLP decreased its position in shares of AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 17.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 91,591 shares of the medical equipment provider's stock after selling 18,763 shares during the period. Marshall Wace LLP owned 0.21% of AxoGen worth $1,509,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. R Squared Ltd bought a new stake in AxoGen during the 4th quarter worth approximately $30,000. US Bancorp DE bought a new stake in AxoGen during the 4th quarter worth approximately $30,000. Harvest Fund Management Co. Ltd bought a new stake in AxoGen during the 4th quarter worth approximately $93,000. Fox Run Management L.L.C. bought a new stake in shares of AxoGen during the fourth quarter valued at approximately $169,000. Finally, Sei Investments Co. purchased a new position in shares of AxoGen in the fourth quarter worth $188,000. Institutional investors own 80.29% of the company's stock.

AxoGen Price Performance

Shares of AxoGen stock opened at $16.18 on Tuesday. The stock has a 50 day moving average of $17.38 and a 200 day moving average of $16.21. AxoGen, Inc. has a 12 month low of $5.55 and a 12 month high of $21.00. The firm has a market cap of $717.49 million, a PE ratio of -50.56 and a beta of 1.00. The company has a current ratio of 3.74, a quick ratio of 2.47 and a debt-to-equity ratio of 0.67.

Insider Activity

In other AxoGen news, Director Amy Mcbride Wendell sold 5,000 shares of AxoGen stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $20.02, for a total transaction of $100,100.00. Following the completion of the transaction, the director now directly owns 97,899 shares of the company's stock, valued at $1,959,937.98. The trade was a 4.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Erick Wayne Devinney sold 15,111 shares of the firm's stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $17.50, for a total transaction of $264,442.50. Following the completion of the sale, the insider now owns 217,762 shares of the company's stock, valued at $3,810,835. This trade represents a 6.49 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.00% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Lake Street Capital assumed coverage on shares of AxoGen in a research note on Monday, March 17th. They set a "buy" rating and a $30.00 target price for the company. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $24.00 target price on shares of AxoGen in a report on Wednesday, March 5th. Finally, Canaccord Genuity Group increased their price target on AxoGen from $22.00 to $26.00 and gave the company a "buy" rating in a research note on Wednesday, February 26th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $22.60.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.